Response Genetics Achieves Milestone Payments Totaling $1,000,000 for Services Provided to GlaxoSmithKline in the Development of

Response Genetics Achieves Milestone Payments Totaling $1,000,000 for Services
Provided to GlaxoSmithKline in the Development of BRAF-Inhibitor Tafinlar(R)

LOS ANGELES, June 4, 2013 (GLOBE NEWSWIRE) -- Response Genetics, Inc.
(Nasdaq:RGDX), a company focused on the development and sale of molecular
diagnostic tests that help determine a patient's response to cancer therapy,
today announced that it has achieved its second milestone payment in
conjunction with the non-exclusive license agreement originated in 2010 with
GlaxoSmithKline ("GSK").

Under the terms of the agreement, GSK gained certain rights to Response
Genetics' proprietary PCR analysis technology and diagnostic expertise to
assess BRAF gene mutations in human tumor samples. Response Genetics earned
its first milestone payment of $500,000 in July of 2012 for submission of the
first Premarket Approval ("PMA") under the contract.On May 29, 2013, GSK
announced the FDA's approval of the PMA, thereby triggering the second
milestone payment of $500,000.

The BRAF gene is responsible for a protein involved in cell signaling, growth
and differentiation. Specific mutations in the gene are found in a subset of
patients with melanoma.Tafinlar® has been approved to treat melanoma that
cannot be surgically removed or metastatic melanoma in adults with the V600E
mutation of BRAF.Tafinlar® is not indicated for patients with wild-type BRAF

"We are extremely pleased to have assisted GSK in achieving this very
important milestone," said Thomas A. Bologna, Chairman and CEO of Response
Genetics. "Response Genetics supports pharmaceutical companies by providing
lab-developed tests that are critical for screening and stratifying patients
during clinical development.The insights that emerge from our work, such as
the association between the specific mutations of BRAF and response to
Tafinlar^®, enable the practice of precision medicine, the selection of a
cancer treatment based on the molecular characteristics of a patient's tumor."

About Response Genetics, Inc.

Response Genetics, Inc. (the "Company") is a CLIA-certified clinical
laboratory focused on the development and sale of molecular diagnostic testing
services for cancer.The Company's technologies enable extraction and analysis
of genetic information derived from tumor cells stored as formalin-fixed and
paraffin-embedded specimens.The Company's principal customers include
oncologists and pathologists.In addition to diagnostic testing services, the
Company generates revenue from the sale of its proprietary analytical
pharmacogenomic testing services of clinical trial specimens to the
pharmaceutical industry.The Company's headquarters is located in Los Angeles,
California.For more information, please visit

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and
the statements of representatives of the Company related thereto contain or
may contain, among other things, certain forward-looking statements, within
the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and
uncertainties.Such statements may include, without limitation, statements
with respect to the Company's plans, objectives, projections, expectations and
intentions, such as the ability of the Company, to provide clinical testing
services to the medical community, to continue to strengthen and expand its
sales force, to continue to build its digital pathology initiative, to attract
and retain qualified management, to continue to strengthen marketing
capabilities, to expand the suite of ResponseDX® products, to continue to
provide clinical trial support to pharmaceutical clients, to enter into new
collaborations with pharmaceutical clients, to enter into areas of companion
diagnostics, to continue to execute on its business strategy and operations,
to continue to analyze cancer samples and the potential for using the results
of this research to develop diagnostic tests for cancer, the usefulness of
genetic information to tailor treatment to patients, and other statements
identified by words such as "project," "may," "could," "would," "should,"
"believe," "expect," "anticipate," "estimate," "intend," "plan" or similar

These statements are based upon the current beliefs and expectations of the
Company's management and are subject to significant risks and uncertainties,
including those detailed in the Company's filings with the Securities Exchange
Commission.Actual results, including, without limitation, actual sales
results, if any, or the application of funds, may differ from those set forth
in the forward-looking statements.These forward-looking statements involve
certain risks and uncertainties that are subject to change based on various
factors (many of which are beyond the Company's control).The Company
undertakes no obligation to publicly update forward-looking statements,
whether because of new information, future events or otherwise, except as
required by law.

CONTACT: Investor Relations Contact:
         Peter Rahmer
         Trout Group
         Company Contact:
         Thomas A. Bologna
         Chairman & Chief Executive Officer

Response Genetics Logo
Press spacebar to pause and continue. Press esc to stop.